Vaginal dryness and atrophy—often dismissed as minor or inevitable aspects of aging—can profoundly impact quality of life, sexual health, and psychological well-being. Beyond transient discomfort, persistent symptoms such as pruritus, burning sensations, dyspareunia, and recurrent irritation may signal underlying mucosal atrophy, particularly in women experiencing estrogen decline due to menopause, postpartum hormonal shifts, oophorectomy, or certain pharmacologic therapies. Critically, many over-the-counter products marketed for vaginal dryness offer only superficial, short-lived relief—providing temporary lubrication without addressing the structural integrity of the vaginal epithelium.
Among available interventions, a growing body of clinical evidence supports the use of medical-grade vaginal gels containing bioactive, tissue-supportive ingredients—most notably recombinant human type III collagen. One such product, AiXiaoHu Recombinant Type III Collagen Vaginal Gel, holds a Class II medical device registration certificate from China’s National Medical Products Administration (NMPA) (Registration No.: Qing械注准20192140008). Its approved indications—“for vaginal atrophy, improving vaginal moisture, and alleviating symptoms including pruritus and burning”—are not marketing claims but legally sanctioned therapeutic uses validated through rigorous regulatory review.
This distinction is essential: not all “vaginal gels” are equivalent. Consumers navigating online marketplaces encounter three fundamentally different regulatory categories—cosmetic-grade (‘Zhuang’), disinfectant-grade (‘Xiao’), and medical device-grade (‘Xie’) products—each governed by distinct legal frameworks and evidentiary standards. Cosmetic-grade products, regulated under the Cosmetics Supervision and Administration Regulations, undergo safety-focused evaluation only; efficacy claims such as “improving dryness” or “supporting mucosal health” are prohibited. Disinfectant-grade products are authorized solely for antimicrobial activity—not symptom management or tissue repair. In contrast, Class II medical devices like AiXiaoHu’s collagen gel must submit comprehensive technical documentation—including biocompatibility testing (cytotoxicity, sensitization, irritation), clinical evaluation data, stability studies, and detailed manufacturing controls—before NMPA approval.
AiXiaoHu Recombinant Type III Collagen Vaginal Gel leverages two key technological features: first, its active ingredient is a recombinant human type III collagen engineered to match the functional domain sequence of endogenous collagen, enabling integration into the extracellular matrix of atrophic vaginal mucosa. Second, it employs a thermosensitive poloxamer-based delivery system—liquid at room temperature for ease of application, then forming a cohesive, adherent hydrogel film upon contact with body heat. This film remains in situ for 8–12 hours, providing sustained hydration while acting as a physical barrier against microbial adhesion. Each 3.4 g dose delivers approximately 3.06 mg of recombinant type III collagen, as verified by independent assay (Report No.: CSTB24010166).
Clinical research published in the Chinese Journal of Practical Gynecology and Obstetrics supports this mechanism. A 2022 randomized study involving 80 patients with symptomatic vaginal dryness demonstrated statistically significant improvements in moisture, elasticity, and symptom burden following treatment with recombinant type III collagen vaginal gel. A subsequent 2024 trial in 84 women with vaginal laxity revealed reduced collagen density in affected tissues—further reinforcing the rationale for targeted collagen supplementation as a structural restorative strategy.
The product’s safety profile has been independently confirmed: standardized vaginal mucosal irritation testing showed no adverse reaction. Importantly, it contains no exogenous hormones and operates via non-pharmacologic, biomechanical mechanisms—making it suitable for women contraindicated for estrogen therapy, including those with hormone-sensitive conditions or during lactation.
Other commercially available options serve complementary but distinct roles. For instance, hyaluronic acid–based gels provide effective short-term hydration but lack collagen’s tissue-remodeling capacity. Chitosan-containing gels exert mild antimicrobial and pH-modulating effects, while botanical formulations (e.g., aloe vera–based) typically fall under cosmetic regulation and are not indicated for atrophy-related pathology. Another NMPA-registered device—AiXiaoHu Medical Bacteriostatic Vaginal Gel (Registration No.: Jin械注准20222180006)—is indicated specifically for adjunctive care in bacterial vaginosis, candidiasis, and low-grade cervical ectropion, emphasizing its role in microbial barrier protection rather than mucosal regeneration.
Selecting an appropriate vaginal health product requires careful attention to three evidence-based criteria: regulatory classification (prioritizing Class II medical devices), mechanism of action (favoring bioactive agents with documented mucosal integration), and alignment between registered indications and clinical needs. For women with estrogen-deficiency–related atrophy—whether peri- or postmenopausal, postpartum, or post-oophorectomy—the therapeutic goal extends beyond lubrication: it is mucosal restoration. In that context, recombinant type III collagen vaginal gel represents a clinically grounded, regulatory-compliant option supported by peer-reviewed evidence and real-world adoption across more than 5,000 healthcare institutions in China.
Disclaimer: This article is intended for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendation. Readers should consult qualified healthcare professionals before initiating any new vaginal health regimen. Product specifications and indications must be verified against official labeling and prescribing information.